Comparative Pharmacology
Head-to-head clinical analysis: AZULFIDINE versus AZULFIDINE EN TABS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZULFIDINE versus AZULFIDINE EN TABS.
AZULFIDINE vs AZULFIDINE EN-TABS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfasalazine is a prodrug that is cleaved by gut bacteria to form 5-aminosalicylic acid (5-ASA) and sulfapyridine. 5-ASA acts locally in the colon to reduce inflammation by inhibiting prostaglandin synthesis and leukotriene formation, antioxidant effects, and inhibition of cytokine production. Sulfapyridine provides additional immunosuppressive effects.
Sulfasalazine is a prodrug that is cleaved by colonic bacteria to 5-aminosalicylic acid (5-ASA) and sulfapyridine. 5-ASA inhibits cyclooxygenase and lipoxygenase pathways, reducing prostaglandin and leukotriene synthesis. It also scavenges reactive oxygen species and inhibits NF-κB activation, leading to anti-inflammatory effects.
Oral, 500 mg to 1 g twice daily, initially 500 mg twice daily, increase to 1 g twice daily after 1 week if tolerated; maximum 3 g/day.
500 mg orally twice daily, titrated to 1 g twice daily after 2 weeks for rheumatoid arthritis; 2 g daily in divided doses for ulcerative colitis.
None Documented
None Documented
Sulfapyridine: 10-14 hours; 5-ASA: 0.6-1.4 hours (rapid acetylation). Clinical context: Twice-daily dosing maintains therapeutic sulfapyridine levels.
Sulfapyridine: 12-15 hours (clinical context: dosing interval typically 6-12 hours due to sulfapyridine accumulation; mesalamine: 0.6-1.5 hours, not clinically relevant)
Renal: 75% (sulfapyridine metabolites), 15% (5-aminosalicylic acid). Biliary/fecal: 10%.
Renal (50% as sulfapyridine metabolites, 33% as acetylsulfapyridine, 15% as sulfapyridine glucuronide, 2% as unchanged sulfapyridine; 15-20% as mesalamine metabolites), biliary/fecal (minimal, primarily mesalamine excreted in feces)
Category C
Category C
Aminosalicylate
Aminosalicylate